The growing understanding of how sequence information can contribute to improved public health is driving global investments in sequencing facilities and programmes. The falling cost and complexity of generating GSD provides opportunities for expanding sequencing capacity; however, challenges to wid...espread implementation remain. This document provides policy-makers and stakeholders with guidance on how to maximize the public health benefit of SARS-CoV-2 genomic sequencing activities in the short and long term as the pandemic continues to unfold. Practical considerations for the implementation of a virus genomic sequencing programme and an overview of the public health objectives of genomic sequencing are covered. This guidance focuses on SARS-CoV-2 but is applicable to other pathogens of public health concern.
more
In the past ten years, the number of forcibly displaced people has nearly doubled. In 2019, the number of people forced to flee (inside and beyond the borders) grew to 79.5 million – the highest ever recorded. Refugee situations continue to increase in scope, scale and complexity, whereas durable ...solutions provided to refugees are at levels that fall well below needs.
more
A Global Analysis of Antimicrobial Resistance and Its Drivers.
Since the first State of the World’s Antibiotics report in 2015, antimicrobial resistance has leveled off in some high-income countries but continues to rise in many low- and middle-income countries (LMICs), where access to antibiotic...s has risen with increases in gross domestic product per capita. Per capita antibiotic consumption in LMICs is lower than in high-income countries, despite a higher infectious disease burden; however, consumption rates are rapidly converging. These trends reflect both better access to antibiotics for those who need them and increases in inappropriate antibiotic use.
more
According to WHO, around 22% of adults in conflict settings have mental health conditions.
This is almost triple to non-conflict settings. There is no generally accepted estimate for children but it is clear that children who are refugees, IDPs or who live in conflict settings have high levels of m...ental health issues.
more
WHO has a unique combination of technical public health and scientific expertise, and a global operational footprint, with field offices in more than 150 countries. In 2020, this global, technical, and operational reach meant WHO was able to support countries around the world in every aspect of COVI...D-19 public health response, from surveillance and laboratory testing to maintaining essential health services in the most vulnerable and fragile contexts.
more
1 February 2021 to 31 January 2022
2 March 2021
Protracted displacement, socio-economic crises aggravated by the COVID-19 pandemic, dire humanitarian needs and protection threats continue to affect the Palestine refugees in Syria, Lebanon and Jordan.
In Syria, the protracted conflict has left 91 per cent of the 438,000 Palestine re...fugees1 estimated to remain in the country in absolute poverty2 and 40 per cent displaced.
more
Вариант вируса, названный «SARSCoV-2, вариант202012/01»,впервые был выявлен в Соединенном Королевстве, и сейчас его циркуляция подтверждена в ряде стран Европейского ре...иона ВОЗ. Он помечен как «вариант, вызывающий обеспокоенность» (VOC), поскольку, по имеющимся данным, он более активнопередается от человека к человеку.
more
This document is an update of the guidance published on 21 March 2020 and contains new evidence and guidance.
Contact tracing – along with robust testing, isolation and care of cases – is a key strategy for interrupting chains of transmission of SARS-CoV-2 and reducing mortality associated with COVID-19.
La recherche des contacts – associée à un dépistage rigoureux, à l’isolement et à la prise en charge des cas – est une stratégie clé pour interrompre les chaînes de transmission du SRAS-CoV-2 et réduire la mortalité associée à la COVID-19.
Основные аспекты обеспечения биологической безопасности в лабораторных условиях в связи с распространением вируса SARS-CoV
28 Jan. 2021. L’objet de ce document est de fournir des orientations provisoires sur la sécurité biologique en laboratoire applicable à l’analyse d’échantillons cliniques issus de patients.